Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a prospective randomized double-blind placebo-controlled dose-escalation study of OMN6 in ABC-associated HABP/VABP
MOH_2024-04-02_013356Phase 2Recruiting
- Sponsor
- Omnix Medical
- Start
- Feb 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OMN-6 in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and Acinetobacter baumannii-calcoaceticus complex infection (6 cohorts), sponsored by Omnix Medical. Primary endpoints: Safety of OMN6 and Pharmacokinetics of OMN6. Started Feb 2024; status: recruiting.
02
Drugs
OMN-6
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Acinetobacter baumannii-calcoaceticus complex infection
Beyond the preview
Go deeper on MOH_2024-04-02_013356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-02_013356.